Bruce Lipton, The POWERFUL You
Jewels talks with Bruce Lipton about stem cells, and current state of affairs. As usual, Dr. Bruce Lipton is wonderful! loaradionetwork.comFrom:Jewels JohnsonViews:56 5ratingsTime:01:01:35More inScience Technology

Here is the original post:
Bruce Lipton, The POWERFUL You - Video

Pain Syndrome Neuropathy
Call: 305-695-7777 For More Information Dr. Kevin Berkowitz and the team at Miami Beach Foot and Ankle surgery are taking great strides in improving your quality of life when it comes to treating pain syndrome and Neuropathy utilizing the science behind amniotic stem cells.From:MiamiFootSurgeryViews:8 0ratingsTime:00:43More inHowto Style

Read the original here:
Pain Syndrome

VTS 01 1
stem cell technology Treatments: One concern of treatment is the risk that transplanted stem cells could form tumors and become cancerous if cell division continues uncontrollably. wikipedia.orgFrom:Peter OngViews:1 0ratingsTime:26:33More inPeople Blogs

See original here:
VTS 01 1 - Video

The Psychodelic Stem Cells perform Come Out and Play (sample)
From:Aleph1963Views:0 0ratingsTime:01:13More inMusic

Follow this link:
The Psychodelic Stem Cells perform Come Out and Play (sample) - Video

Stem Cells Arthritis Treatment Guided Mesenchymal Stem Cell Layering Technique... A Breakthrough?
The next series of videos will focus on stem cells and arthritis treatment. The first thing I #39;m going to do is describe the guided mesenchymal stem cell layering technique. This is our proprietary method. If you have osteoarthritis and are looking for an alternative to joint replacement, you might want to pay attention. The Venn diagram shows the ingredients that go into the procedure- mesenchymal stem cells from marrow and fat, growth factors, from platelet-rich plasma, matrix, and a stabilizing gel (thrombin). What is different about our technique compared with others is we are able to induce a precise area of injury using direct guidance with arthroscopy and diagnostic ultrasound. The end result is cartilage growth and repair. If you #39;re an active individual who wants to avoid the metal and plastic and the potential complications associated with a joint replacement, there is an alternative. If you have questions or want more information go to http://www.arthritistreatmentcenter.comFrom:Nathan WeiViews:2 0ratingsTime:19:10More inScience Technology

Read the rest here:
Stem Cells Arthritis Treatment Guided Mesenchymal Stem Cell Layering Technique... A Breakthrough? - Video

Cure for autism?
Autism is a national epidemic in the United States, with one out of every 88 children being diagnosed on the spectrum. Anna Kooiman sits down with an expert, who is leading a ground-breaking clinical trial that uses cord blood stem cells in the hopes of curing the disorderFrom:FoxNewsChannelViews:30 1ratingsTime:05:00More inNews Politics

See original here:
Cure for autism? - Video

Public release date: 5-Nov-2012 [ | E-mail | Share ]

Contact: NHLBI Communications NHLBI_news@nhlbi.nih.gov 301-496-7510 NIH/National Heart, Lung and Blood Institute

Administering to patients stem cells derived from their own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial supported by the National Institutes of Health.

The results of the trial, called Transplantation In Myocardial Infarction Evaluation (TIME), mirror a previous, related study, LateTIME, which found that such cells (called autologous stem cells) given two to three weeks after a heart attack did not improve heart function. Both TIME and LateTIME were conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute.

The findings will be presented Tuesday, Nov. 6, at the American Heart Association (AHA) 2012 Scientific Sessions in Los Angeles and will appear concurrently in the Journal of the American Medical Association.

"This study was extremely valuable even though it did not provide a demonstrated health benefit after six months," said Sonia Skarlatos, Ph.D., deputy director of NHLBI's Division of Cardiovascular Sciences and member of the CCTRN. "Heart stem cell therapy research is still in its infancy, and results from early trials have varied greatly due to differences in the numbers of stem cells injected, the delivery methods used, and the compositions of the study populations. With TIME and LateTIME, we have established both safety and baseline results in two large studies that followed the same procedures for growing and then administering stem cells. This standard will inform the next steps in research on the use of stem cells to repair damaged hearts."

"With this baseline now set, we can start to adjust some of the components of the protocol to grow and administer stem cell to find cases where the procedure may improve function," added fellow CCTRN member Jay Travese, M.D., of the Minneapolis Heart Institute, who will present the results at the meeting. "For example, this therapy may work better in different population groups, or we might need to use new cell types or new methods of delivery."

Skarlatos noted that another advantage of the TIME study is that CCTRN is storing samples of the stem cells taken from the participants. Investigators can examine the relationship between people who showed significant improvement during the study and the characteristics of their stem cells. Such a comparison may offer insights on the cell traits that are associated with clinical improvement.

Between July 2008 and February 2011, TIME researchers enrolled 120 volunteers (average age 57, 87.5 percent male) who suffered from moderate to severe impairment in their left ventricles the part of the heart that pumps oxygen-rich blood to the body and had undergone stenting procedures following heart attacks. Those selected for the trial were assigned randomly to one of four groups: day three after heart attack stem cell injection, day three after heart attack placebo injection, day seven after heart attack stem cell treatment, or day seven after heart attack placebo treatment. The researchers developed a method of processing and purifying the stem cells to ensure that participants in the stem cell groups received a uniform dose of 150 million cells about 8 hours after the cells were harvested from their bone marrow. This ensured that results would not be skewed by differences in the quantity or quality of stem cells administered.

Researchers assessed heart improvement six months after stem cell therapy by measuring the percentage of blood that was pumped out of the left ventricle during each contraction (known as the left-ventricular ejection fraction, or LVEF). The study found no significant differences between the change in LVEF readings at the six-month follow-up in either the day three or the day seven stem cell groups compared with placebo groups or with each other. Every group showed about a three percent improvement in LVEF.

Read more from the original source:
Therapy with bone marrow-derived stem cells does not improve short-term recovery after heart attack

Men who lose the ability to produce sperm after chemotherapy might one day be able to regain their fertility. That's because, for the first time, infertility has been reversed in a male primate using an injection of stem cells.

Cancer drugs often work by destroying rapidly dividing cells, as these are a typical feature of cancer. Unfortunately, the drugs can also kill other rapidly dividing cells, including those that produce sperm. Some men choose to freeze sperm samples before therapy so they can use them for artificial insemination at a later date, but this is not an option for boys who have not yet reached puberty.

Kyle Orwig at the University of Pittsburgh School of Medicine in Pennsylvania may have a solution. He says that while boys don't make sperm cells, they do possess "spermatogonial" stem cells that will eventually produce them.

To see if these stem cells could be used to restore fertility, Orwig and his team took samples of the cells from the testes of prepubescent and adult male rhesus macaques, and froze them. The monkeys were then given chemotherapy agents known to shut down sperm production. A few months later, the researchers injected each monkey's own spermatogonial stem cells back into its testes.

Sperm production was re-established in nine of the 12 adult animals and started normally in three out of five prepubescent animals once they reached maturity. The resulting sperm were used to fertilise eggs and produce healthy embryos.

"I think this is the best option we have ever had," says Renee Reijo Pera, director of Stanford University's Center for Human Embryonic Stem Cell Research and Education, who wasn't involved in the study. "I know a lot of people have thought about doing this before but no has ever been able to successfully demonstrate this in a clinical setting with a species genetically very similar to us."

Orwig says there are some concerns that implanting stem cells could reintroduce cancer cells that may have been present in the original tissue. However, centres in the US and Europe are already banking testicular tissue for boys in the hope that new stem cell-based therapies will become available.

"In the most optimistic scenario our research suggests a man could have his own stem cells transplanted, giving him the opportunity to have children via natural intercourse," Orwig says. It's not yet ready for clinical translation, he says, "but it's an important step forward".

Journal reference: Cell Stem Cell, DOI: 10.1016/j.stem.2012.07.017

If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.

Read more from the original source:
Sperm stem cells restore male fertility

Study Highlights:

LOS ANGELES, Nov. 5, 2012 (GLOBE NEWSWIRE) -- Stem cells taken from patients or donors can treat people with enlarged hearts safely and with similar effectiveness, according to late-breaking clinical trial results presented at the American Heart Association's Scientific Sessions 2012.

The Comparison of Allogeneic vs. Autologous Bone Marrow Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients with Ischemic Cardiomyopathy trial (POISEIDON) is also published in the Journal of the American Medical Association.

"This cell therapy clearly had some clinical benefits and the mesenchymal stem cells from donors were just as safe as those from the recipient," said Joshua Hare, M.D., the lead study author. "Even in patients who had heart attacks several decades before treatment, both donor and recipient stem cells reduced the amount of scarring substantially, by one-third."

The mesenchymal stem cells (MSCs) -- unique because the body's protective antibodies don't attack them -- are found in adults' bone marrow.

Previous studies indicated that MSCs might improve heart muscle function in patients with heart scarring from a prior heart attack. Heart muscle weakening from such scars (ischemic cardiomyopathy) is the most common cause of debilitating and deadly congestive heart failure.

The 13-month trial is the first to compare the safety and efficacy of MSCs taken from the patients themselves against MSCs provided by donors. Thirty patients with chronic ischemic cardiomyopathy received various doses of MSCs. Half received their own cells, while the other half received donor cells. Heart failure class improved in 28 percent of those receiving donor cells, and in 50 percent of those receiving their own cells.

Regenerating new heart muscle with MSCs requires growing large amounts of the stem cells, which takes six to eight weeks. Using already-prepared donor cells might avoid this delay to treatment.

"Because antibodies don't attack MSCs, donor cells can be prepared in advance and stored until needed," said Hare, a professor of medicine and director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine in Florida. "Perhaps using donor cells is the more feasible approach."

The stem cells were delivered directly into the damaged area of patients' heart muscle using a catheter with a needle tip. "An additional important finding was the safety of this new cardiac catheterization technique," said study co-author Alan Heldman, M.D., a cardiologist and Professor of Medicine in the University of Miami Health System, who performed the minimally-invasive procedures.

Read more:
Stem Cells From Patients or Donors May Help Treat Diseased Hearts